JPRN-jRCT2080223421已完成1 期
A Phase 1 Study of CS-3150 Evaluation of Safety, Pharmacokinetics, and Pharmacodynamics after Multiple Oral Administration in Japanese Healthy Adult Male Subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
Esaxerenone was well tolerated in multiple oral administration of the drug at doses of 10 mg to 100 mg once daily for 10 days in Japanese healthy male subjects.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 45age old（—）
- 性别
- Male
入选标准
- •1)Japanese male
- •2)Persons >= 20 years and =< 45 years of age at the time of informed consent
- •3)Persons with a body mass index (BMI; calculated by body weight [kg]/height [m]2) of >= 18.5 kg/m2 and < 25.0 kg/m2 at the screening examination
排除标准
- •1)Persons with hypersensitivity or idiosyncratic reactions to a drug, (such as penicillin allergy)
- •2)Persons with drug or alcohol dependence
研究者
相似试验
已完成
1 期
A Phase 1 Study of CS-3150 Evaluation of Safety, Pharmacokinetics, and Pharmacodynamics after Single Oral Administration in Japanese Healthy Adult Male SubjectsHealthy volunteersJPRN-jRCT2080223418DAIICHI SANKYO Co.,Ltd.48
已完成
1 期
Clinical Pharmacology Study of CS-3150 A single dose study to assess the absolute bioavailability and effect of food on the pharmacokinetics of CS-3150 in Japanese healthy subjectsHealthy volunteersJPRN-jRCT2080223397DAIICHI SANKYO Co.,Ltd.24
已完成
1 期
ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With ObesityObesityNCT04890873ERX Pharmaceuticals48
已完成
1 期
Clinical Pharmacology Study of CS-3150 Evaluation of the effect of repeated dose of itraconazole orally administered to healthy Japanese adult male on the pharmacokinetics of CS-3150Healthy volunteersJPRN-jRCT2080223231DAIICHI SANKYO Co.,Ltd.20
进行中（未招募）
1 期
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsNon-Small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal AdenocarcinomaAdvanced Solid TumorNCT05462717Revolution Medicines, Inc.222